| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:29812931 | IVR | 24 mg/kg | 24 mg/kg | Increased hypothalamus weights | Neurological endocrine-mediated perturbations |
| IVR | 24 mg/kg | 24 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 24 mg/kg | 24 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 24 mg/kg | 24 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 24 mg/kg | 24 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 24 mg/kg | 24 mg/kg | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 24 mg/kg | 24 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Increased hypothalamus weights | Neurological endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Increased hypothalamus weights | Neurological endocrine-mediated perturbations | |
| PMID:33646749 | IVR | 22.5 mg/kg/day | 22.5 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations |
| IVR | 22.5 mg/kg/day | 22.5 mg/kg/day | Decreased body weights in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 7.5 - 22.5 mg/kg/day | 7.5 - 22.5 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 22.5 mg/kg/day | 22.5 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 9 mg/kg/day | 9 mg/kg/day | Increased cowper's gland weights | Reproductive endocrine-mediated perturbations | |
| IVR | 22.5 mg/kg/day | 22.5 mg/kg/day | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 22.5 mg/kg/day | 22.5 mg/kg/day | Increased weights of accessory sex organs | Reproductive endocrine-mediated perturbations | |
| PMID:35193068 | IVTH | 0.0000005 M | 0.0000005 M | Increased estrogen levels | Reproductive endocrine-mediated perturbations |
| PMID:35470848 | IVR | 5 mg/L | 5 mg/L | Induce behavioral changes | Neurological endocrine-mediated perturbations |
| IVR | 5 mg/L | 5 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/L | 5 mg/L | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/L | 1 - 5 mg/L | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:35725088 | IVR | 5 mg/L | 5 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| PMID:36963690 | IVTH | 0.00000001 - 0.000017 M | 0.00000001 - 0.000017 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.0001 M | 0.000001 - 0.0001 M | Oxidative stress in placenta | Reproductive endocrine-mediated perturbations | |
| PMID:37094483 | IVTH | 0.000002 M | 0.000002 M | Oxidative stress in thyroid cells | Metabolic endocrine-mediated perturbations |
| IVTH | 0.0000005 - 0.000002 M | 0.0000005 - 0.000002 M | Affects thyroid hormone synthesis | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000001 - 0.000002 M | 0.000001 - 0.000002 M | Oxidative stress in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000005 - 0.000002 M | 0.0000005 - 0.000002 M | Affects iodine uptake into thyroid | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.